Roy F. Waldron
Directeur/Bestuurslid bij Starton Therapeutics, Inc.
Profiel
Roy F.
Waldron is currently a Director at Starton Therapeutics, Inc. and an Independent Director at HWEL Holdings Corp.
He previously worked as the Chief Intellectual Property Counsel & Senior VP at Pfizer Inc. Waldron received his undergraduate degree from Dartmouth College, his doctorate from Yale University, and his graduate degree from New York University School of Law.
Actieve functies van Roy F. Waldron
| Bedrijven | Functie | Begin |
|---|---|---|
Starton Therapeutics, Inc.
 Starton Therapeutics, Inc. BiotechnologyHealth Technology Starton Therapeutics, Inc. is a clinical-stage biotechnology platform company that focuses on transforming standard of care therapies with proprietary continuous delivery technology. The company is based in Paramus, NJ. The company's goal is to provide continuous treatment to people with cancer so they can live better and longer. Starton's proprietary transdermal technology is intended to increase the efficacy of approved drugs, make them more tolerable, and expand their potential use. The company was founded in 2017 by Pedro Lichtinger, who has been the CEO since 2017. | Directeur/Bestuurslid | 01-05-2019 |
Eerdere bekende functies van Roy F. Waldron
| Bedrijven | Functie | Einde |
|---|---|---|
| PFIZER, INC. | Corporate Officer/Principal | - |
Opleiding van Roy F. Waldron
| New York University School of Law | Graduate Degree |
| Yale University | Doctorate Degree |
| Dartmouth College | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| PFIZER, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Starton Therapeutics, Inc.
Starton Therapeutics, Inc. BiotechnologyHealth Technology Starton Therapeutics, Inc. is a clinical-stage biotechnology platform company that focuses on transforming standard of care therapies with proprietary continuous delivery technology. The company is based in Paramus, NJ. The company's goal is to provide continuous treatment to people with cancer so they can live better and longer. Starton's proprietary transdermal technology is intended to increase the efficacy of approved drugs, make them more tolerable, and expand their potential use. The company was founded in 2017 by Pedro Lichtinger, who has been the CEO since 2017. | Health Technology |
